Table 4 Subjects demographic and clinical characteristics
Characteristics | SJIA Flare | SJIA Quiescence | POLYJIA Flare | POLYJIA Quiescence |
|---|---|---|---|---|
N1 | 22 | 24 | 17 | 8 |
Female/Male2 | 11/11 | 11/13 | 14/3 | 7/1 |
African- American | 1 | 2 | 1 | 1 |
Asian | 3 | 3 | 0 | 0 |
Caucasian | 8 | 10 | 11 | 4 |
Caucasian Hispanic | 10 | 9 | 5 | 3 |
Median age (yr) at disease onset (range) | 5.8 (1.7 to 15.7) | 5.8 (1.4 to 15.7) | 8.6 (1.2 to 15.1) | 8.6 (1.2 to 15.1) |
Median age (yr) at sample collection (range) | 9.3 (3.5 to 16.6) | 11.1 (2.4 to 18.9) | 13.4 (5 to 18.7) | 14.1 (6.1 to 19.2) |
Median WBC (x103/ul) (range) | 13.3 (5.3 to 27.4)3 | 6.9 (3.4 to 11.8) | 8.8 (4.9 to 15.1) | 7.5 (5.6 to 9.8) |
Median platelets (x103/ul) (range) | 461 (257 to 814)4 | 280 (170 to 400) | 384 (211 to 512)5 | 283 (224 to 432) |
Median ESR (mm/h) (range) | 81 (11 to 121)6 | 5.5 (0 to 18) | 31 (7 to 78)7 | 9 (2 to 15) |
Median joint count (range) | 9 (1 to 28)8 | 0 (0 to 1) | 25 (3 to 62)9 | 0 (0) |
Median prednisone dose, mg/kd/day (range) | 0.01 (0 to 0.53)10 | 0 (0 to 1.1) | 0 (0 to 0.1) | 0 (0 to 1) |
Methotrexate/ total no. samples (%) | 8/22 (36%) | 7/24 (29%) | 10/17 (59%) | 6/8 (75%) |
Anti-TNF/total no. samples (%) | 7/22 (32%) | 9/24 (38%) | 5/17 (29%)11 | 5/8 (63%)11 |
IL-1RA/total no. samples (%) | 1/22 (5%) | 2/24 (8%) | 0/17 | 0/8 |